SMITHKLINE-STERLING WOULD HAVE 49% OF COMBINED $2 BIL. OTC BUSINESS
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE-STERLING WOULD HAVE 49% OF COMBINED $2 BIL. OTC BUSINESS centered in North America (with nearly $1 bil. in sales), 22% in Europe, 12% in Latin America, 5% in Australia/New Zealand, 2% in Japan and 10% in other international markets. The merged business will be "number one in OTC medicines worldwide, the market leader in European and international markets, and number four in the U.S.," SmithKline Beecham calculated.